Navigation Links
Akron Relationship with Israeli Incubator, Targetech, Shows Promise
Date:5/19/2011

AKRON, Ohio, and NETANYA, Israel, May 19, 2011 /PRNewswire-USNewswire/ -- The Targetech Innovation Center, supported by a strategic partnership with the City of Akron, Ohio, has a developing pipeline of biomedical device opportunities poised to begin commercialization partnerships in the United States.  

"This is an exciting development in the strategic partnership that we initially formed with Targetech.  From this effort, we will see more companies locating to Akron.  This will provide more jobs for our residents.  I am extremely pleased that this creative step I took several years ago has worked so well," said Mayor Donald L. Plusquellic.

To assist developing companies in the Targetech pipeline, the incubator has broadened its strategic relationships in the Akron and Cleveland regions through a new relationship with BioEnterprise, the region's biomedical business development initiative.  BioEnterprise will assist select Targetech portfolio firms in developing their U.S. strategies and supporting the establishment of their U.S. operations in Ohio.

"We are very fortunate to have the City of Akron and BioEnterprise as partners," said Azriel Kadim, CEO of Targetech.  "The City of Akron was an early investor in incubator companies at Targetech and we are now positioning our most promising biomedical companies to establish their US presence in Akron.  This new relationship with BioEnterprise will further enhance the likelihood of success of our portfolio companies."  

"BioEnterprise, and our Northeast Ohio economic development partners, have many years of experience in supporting Israeli companies such as NI Medical in establishing their US presence," said Baiju R. Shah, BioEnterprise President and CEO.  "We are pleased to be able to support the City of Akron's partnership with the Targetech incubator through this relationship."  

"By focusing on markets and technologies where there is a strategic overlap between the incubator's pipeline and our local strengths we increase the likelihood of success and therefore drive IRR for Targetech's investors," said Neil Wyant, Targetech's Akron-based chairman.  "The relationship with BioEnterprise brings strong resources to our effort to commercialize biomedical technologies locally."

About Targetech:

Targetech Innovation Center is a dynamic high technology Incubator located in Netanya, Israel and operating under the Israeli Chief Scientist High-Tech Incubator Program.  Targetech has adopted a commercialization model focused on medical devices and biomaterial applications. Under this model Targetech engages US opinion leaders to provide early and ongoing guidance and strategic access to important world markets. In addition, Targetech provides financial and operating resources during the incubator period as well as access to follow-on financing. By combining early market input and ongoing guidance, access to leading clinical resources in Israel and in the US, the model reduces market and technical risk thereby increasing the likelihood of global success.  For more information, see http://www.targetech.co.il.

About BioEnterprise:

BioEnterprise is a business formation, recruitment, and acceleration effort designed to support the growth of bioscience companies. Located in Cleveland, BioEnterprise provides management counsel and support services to health care companies.  BioEnterprise partners are Case Western Reserve University, Cleveland Clinic, University Hospitals, Summa Health System, and the Austen BioInnovation Institute in Akron. Additional technology partners include the NASA Glenn Research Center, Cleveland State University, NorTech, and BioOhio.  The initiative comprises the collective activities of BioEnterprise and its partners' commercialization offices: the Case Office of Technology Transfer, Cleveland Clinic Innovations, University Hospitals Case Medical Center - Center for Clinical Research and Summa Enterprise Group. The combined efforts of these groups has created, recruited, and accelerated more than 100 companies in eight years.  For more information, see www.bioenterprise.com.  

CONTACT: Kobi Elad of Targetech, kobi@targetech.co.il, +972.988.5115


'/>"/>
SOURCE Targetech Innovation Center
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
2. MedClean Technologies Forms Co-Promotion Relationship With Covidien, Leading Global Healthcare Products Manufacturer
3. Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
4. UNC Selects MedAssurant to Support Investigation of Relationship Between Insulin and Cancer Development
5. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
6. Corporate Affairs Role in Internal and External Relationships Key to Organizational Success
7. LearnSomething, Inc. Announces New Relationship With ASHP
8. Wolters Kluwer Health and the Joanna Briggs Institute Enter Exclusive Relationship to Deliver Evidence-Based Clinical Resources
9. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
10. Southwest Hospitals MRI Centers Commitment to State-of-the-Art Technology at the Heart of Nearly 20-Year Relationship with MedInformatix RIS
11. Hot Times in the City: As Summer Temperatures Soar, Pulse of Passion Survey Reveals What Makes Americans Sizzle in Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
Breaking Medicine Technology:
(Date:3/24/2017)... FL (PRWEB) , ... March 24, 2017 , ... ... Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at ... Endoscopy Centers in 87th Ave., Miami, FL. , The HyGIeaCare® ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, ... Master in Frederick, MD. Judy says, “I am passionate about sharing Reiki as ... a very difficult and challenging time.” , A Certified Medical Reiki™ Master trained ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and enlightened ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World War ... munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization declared ... be four million Zika-related cases in the Americas within the next year. Lyme disease ... reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect ...
Breaking Medicine News(10 mins):